Standard BioTools Inc. (LAB) SEC Filings & Earnings Calls

Transaction subject to customary closing conditions; risk of non-completion or unfavorable terms.

“subject to customary closing conditions” · word for word

Nasdaq delisting risk

“On July 22, 2026, we received a written notice from Nasdaq notifying us that we again did not meet the Bid Price Requirement.” · word for word

Merger completion risk

“The completion of the Merger is dependent on a number of factors that may be beyond our control, including, among other things, market conditions, regulatory approval and stockholder approval.” · word for word

Significant stockholder dilution

“Treeline stockholders and our stockholders are expected to own approximately 84% and 16%, respectively, of the combined company’s outstanding shares on a fully diluted basis.” · word for word

Termination fee obligation

“Upon termination of the Merger Agreement under specified circumstances... we will be required to make a payment to Treeline equal to $16.1 million in cash.” · word for word

Revenue decline across all segments; consumables down 10% YoY due to US Academia spend uncertainty.

“Consumables revenue down 10% year-over-year, compared against particularly strong prior year results and continued US Academia spend uncertainty.”

Pending merger with Treeline Biosciences creates execution risk and guidance withdrawal.

“Standard BioTools is withdrawing its full year 2026 revenue outlook given the pending merger with Treeline Biosciences.” · word for word

Net loss widened 21% YoY due to one-time transaction costs.

“Net loss for the second quarter of 2026 was $21.5 million from continuing operations, compared to a net loss of $17.7 million in the second quarter of 2025, representing a change of $3.8 million or 21%.” · word for word

Merger completion risk: Treeline merger subject to stockholder approval and customary conditions.

“The Treeline transaction is expected to close by the end of 2026, subject to approval by Standard BioTools stockholders and other customary closing conditions.”

Delisting risk: Failure to regain compliance could lead to delisting from Nasdaq.

“Company received notice of non-compliance with minimum bid price requirement.”

Potential dilution from new equity plans.

“New equity plan and ESPP share increase approved.”

Merger execution risk; stockholder approval required; potential dilution.

“Merger subject to stockholder approval and other closing conditions.”

Potential retention risk if change of control occurs; increased severance obligations.

“Severance benefits include 150% of salary plus bonus and equity acceleration upon qualifying termination within change of control period.”

Nasdaq Delisting Risk

“On April 20, 2026, we received a written notice from Nasdaq notifying us that, because the closing bid price for our common stock had fallen below $1.00 per share for 30 consecutive business days, we no longer met the minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market.” · word for word

Macroeconomic Pressure on Instrument Sales

“The decline in instruments revenue reflects continued macroeconomic pressures on customer spending, including budgetary limitations and constrained funding environments that have impacted purchase timing and deal closure rates.” · word for word

Litigation Exposure

“In December 2023, prior to the Company's merger with SomaLogic, a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain of its officers and directors alleging breach of fiduciary duty in connection with the proposed merger.” · word for word

Palamedrix Indemnification Obligation

“As of March 31, 2026, the Company has accrued $3.3 million related to this indemnification obligation.” · word for word

Instrument revenue decline due to capital-constrained end-markets may persist.

“Instruments revenue was $4.5 million in the first quarter of 2026, down 33% year-over-year. Instrument revenue in the quarter, compared against particularly strong prior year results, remained impacted by capital-constrained end-markets.” · word for word

Constrained Americas Academic spending environment

“In 2025, our performance was marked by a transformative transaction backed by solid operational execution amid a constrained Americas Academic spending environment.” · word for word

Dependence on key personnel retention

“The Board determined that leadership continuity was critical during this period of portfolio simplification, operating model streamlining, and strengthened balance sheet positioning, and approved these awards to reinforce stability and sustained execution of the Company's strategic and financial priorities.” · word for word

Risk of delisting if unable to regain compliance within 180 days; may need reverse stock split.

“Company has until October 19, 2026, to regain compliance; may transfer to Nasdaq Capital Market for additional 180 days.”

Macroeconomic Pressure on Customer Spending

“The decline was primarily driven by a $4.3 million decrease in consumables revenue, due to macroeconomic pressures on customer spending, including budgetary limitations and constrained funding environments.” · word for word

NIH Funding Disruption

“In particular, upon taking office in January 2025, the Trump administration effectively prevented the National Institutes of Health from reviewing and awarding grants, or paying out funds under already awarded grants, including for research or other projects that may involve our products and services.” · word for word

Tariff Cost Pressure

“Any imposition of or increase in tariffs or other restrictions on imports of materials on which our products rely, as well as corresponding price increases for such materials available domestically, if any, could increase our costs.” · word for word

Litigation Risk (Palamedrix Milestone Payments)

“SRS claims that, had the technology been successfully developed and commercialized, SomaLogic would have been required to pay up to $17.5 million in three sales-based milestone payments.” · word for word

Customer Concentration

“A significant reduction in orders from one or more of these customers could adversely affect our revenue and operating results.” · word for word

Revenue decline continues due to consumables project funding declines and capital-constrained end-markets.

“Revenue down 4% YoY in Q4, down 6% in FY2025; Consumables down 17% YoY”

Restructuring charges of $14.8M in FY2025 indicate ongoing operational transition.

“Operating expenses included $14.8 million in restructuring and related charges” · word for word

Adjusted EBITDA remains negative, though improving; path to profitability depends on cost savings and revenue stabilization.

“Adjusted EBITDA loss $15.8M in Q4, $62.6M in FY2025”

NIH funding pressures and U.S. export controls/tariffs could impact continuing operations.

“Anticipated NIH funding pressures; the expected effect from U.S. export controls and the expected impact from tariffs.” · word for word

Earnout payments contingent on revenue targets; may not be fully realized.

“Eligible to receive up to $75 million in earnout payments... payable upon the achievement of specified targets.” · word for word

Preliminary results are subject to audit adjustments and may change.

“The Company's preliminary financial results are unaudited and based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures.” · word for word

Integration and divestiture risks related to SomaLogic sale and prior acquisitions.

“risks that the anticipated benefits and synergies of announced divestures and prior and potential future acquisitions and the integration of any such businesses may not be fully realized”

Revenue decline across all segments with margin contraction.

“Revenue -11% YoY; gross margin 48.5% vs 54.9%.”

Restructuring execution risk including workforce reduction and facility consolidation.

“20% workforce reduction; consolidation of South San Francisco into Singapore.”

Capital-constrained end-markets impacting instrument sales.

“Instrument revenue impacted by capital-constrained end-markets globally.”

Project funding declines in flow and microfluidics.

“Lower consumables revenue reflected project funding declines in flow and microfluidics.”

Revenue decline from macro pressures

“The revenue decline was anticipated by management and reflects continued macroeconomic pressures on customer spending, including budgetary limitations and constrained funding environments” · word for word

Divestiture execution risk

“The consummation of the Transaction is subject to customary closing conditions, including, among others, the expiration or termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.” · word for word

Restructuring disruption

“Restructuring and related charges 9,428 2,341 7,087 303 %” · word for word